Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $105,892.60 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 8,338 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.70, for a total transaction of $105,892.60. Following the sale, the insider now owns 178,692 shares in the company, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Masaru Matsuda also recently made the following trade(s):

• On Tuesday, November 19th, Masaru Matsuda sold 1,775 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $9.68, for a total value of $17,182.00.

Arcutis Biotherapeutics Trading Down 5.8 %

ARQT stock opened at $12.42 on Friday. The business has a fifty day moving average price of $13.68 and a 200 day moving average price of $11.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.46 and a quick ratio of 2.38. Arcutis Biotherapeutics, Inc. has a fifty-two week low of $5.38 and a fifty-two week high of $16.20. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.94 and a beta of 1.29.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The company had revenue of $44.76 million during the quarter, compared to analyst estimates of $38.05 million. Analysts expect that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of Arcutis Biotherapeutics in a report on Monday, January 13th. Finally, Mizuho boosted their target price on shares of Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, January 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.60.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd acquired a new position in shares of Arcutis Biotherapeutics during the third quarter worth approximately $25,000. Venturi Wealth Management LLC bought a new position in Arcutis Biotherapeutics in the 4th quarter worth approximately $46,000. Algert Global LLC acquired a new position in Arcutis Biotherapeutics during the 2nd quarter worth $97,000. Erste Asset Management GmbH bought a new position in Arcutis Biotherapeutics in the 3rd quarter valued at $104,000. Finally, LVW Advisors LLC acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $166,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.